World class scientist and drug developer in fields of inflammation and respiratory diseases; international authority on leukotriene and eicosanoid biochemistry; experienced integrator of chemistry, biology and metabolism drug development teams; outstanding motivational, interpersonal and communication skills
Selected Publications
Jilly F. Evans, Ryan W. Rue, Alexander R. Mukhitov, Kseniya Obraztsova, Carly J. Smith, Vera P. Krymskaya
: Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor
Biomolecules 10(1): 28, Jan 2020.
Obraztsova K, Evans JF and Krymskaya VP.: Syndecan-2: Old player in a new field. Am J Respir Cell Mol Biol 60(1): 611-612, Jan 2019.
Blanca E. Himes, Kseniya Obraztsova, Lurong Lian, Maya Shumyatcher, Ryan Rue, Elena N. Atochina-Vasserman, Stella K. Hur, Marisa S. Bartolomei, Jilly F. Evans, Vera P. Krymskaya: Rapamycin-independent IGF2 expression in Tsc2-null mouse embryo fibroblasts and human lymphangioleiomyomatosis cells
PLoS One. 13(5): e0197105, May 2018.
Bain Gretchen, Shannon Kristen E, Huang Fei, Darlington Janice, Goulet Lance, Prodanovich Patricia, Ma Gina L, Santini Angelina M, Stein Adam J, Lonergan Dave, King Christopher D, Calderon Imelda, Lai Andiliy, Hutchinson John H, Evans Jilly F: Selective inhibition of autotaxin is efficacious in mouse models of liver fibrosis. The Journal of pharmacology and experimental therapeutics 360(1): 1-13, Jan 2017.
Sun Ying, Zhang Weici, Evans Jilly F, Floreani Annarosa, Zou Zhengsheng, Nishio Yukiko, Qi Ruizhao, Leung Patrick S C, Bowlus Christopher L, Gershwin M Eric: Autotaxin, pruritus and primary biliary cholangitis (PBC). Autoimmunity reviews 15(8): 795-800, Aug 2016.
Stein Adam J, Bain Gretchen, Prodanovich Pat, Santini Angelina M, Darlington Janice, Stelzer Nina M P, Sidhu Ranjinder S, Schaub Jeffrey, Goulet Lance, Lonergan Dave, Calderon Imelda, Evans Jilly F, Hutchinson John H: Structural basis for inhibition of human autotaxin by four potent compounds with distinct modes of binding. Molecular pharmacology 88(6): 982-92, Dec 2015.
Schafer P H, Parton A, Capone L, Cedzik D, Brady H, Evans J F, Man H-W, Muller G W, Stirling D I, Chopra R: Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cellular signalling 26(9): 2016-29, Sep 2014.
Bäck Magnus, Powell William S, Dahlén Sven-Erik, Drazen Jeffrey M, Evans Jilly F, Serhan Charles N, Shimizu Takao, Yokomizo Takehiko, Rovati G Enrico: Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7. British journal of pharmacology 171(15): 3551-74, Aug 2014.
Bain Gretchen, King Christopher D, Schaab Kevin, Rewolinski Melissa, Norris Virginia, Ambery Claire, Bentley Jane, Yamada Masanori, Santini Angelina M, van de Wetering de Rooij Jeroen, Stock Nicholas, Zunic Jasmine, Hutchinson John H, Evans Jilly F: Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor. British journal of clinical pharmacology 75(3): 779-90, Mar 2013.
Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi A K, Kang J, Karasawa S, Carmel G, Jackson P, Abbasian M, Mahmoudi A, Cathers B, Rychak E, Gaidarova S, Chen R, Schafer P H, Handa H, Daniel T O, Evans J F, Chopra R: Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26(11): 2326-35, Nov 2012.
back to top
Last updated: 08/24/2020
The Trustees of the University of Pennsylvania
